Infographic: teprotumumab for the treatment of active thyroid eye disease

Fig. 1 Full size image Teprotumumab is a monoclonal antibody therapy targeting insulin-like growth factor-1 receptor (IGF-IR) for thyroid eye disease (TED). Teprotumumab is an alternative to traditional immunosuppression [ 1 , 2 ]. This infographic summarises the design and results of the multicentre phase III “OPTIC” trial: Treatment of Graves’ O rbitopathy (Thyroid Eye Disease) to Reduce P roptosis with Pro t umumab I nfusions in a Randomized, Placebo-Controlled, Trial, Investigating C linical Efficacy. This trial evaluated the efficacy and safety of teprotumumab in active TED compared to placebo [ 3 ]. Teprotumumab reduced proptosis, Clinical Activity Score, diplopia and improved patient reported quality of life [ 3 ]. Created in BioRender. Berman, G. (2026) https://BioRender.com/yb3ap06 .